AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment …
– ABBVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ (upadacitinib) for the
Nasal Spray Resurrected After Showing Clinical Benefits for PVST medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
- New analyses from CD-PROBE study evaluating sustained efficacy and tolerability of onabotulinumtoxinA in patients with cervical dystonia
- New analyses from the ASPIRE study on patient adherence to onabotulinumtoxinA for management of spasticity
- Data on onabotulinumtoxinA treatment in adult patients with overactive bladder and in pediatric patients with neurogenic detrusor overactivity
- Meta-analysis of immunogenicity rates across 10 therapeutic and aesthetic indications, and